Previous close | 180.10 |
Open | 180.10 |
Bid | 157.60 |
Ask | 162.00 |
Strike | 110.00 |
Expiry date | 2024-06-21 |
Day's range | 180.10 - 180.10 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general pu